Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.